ADVANCED ONCOLOGY CERTIFIED NURSE PRACTITIONER – PRACTICE
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains:
- Scientific Basis for Practice
- Health Promotion, Screening, and Early Detection
- Diagnosis and Staging
- Treatment Modalities (Chemotherapy, Radiation, Surgery, Immunotherapy)
- Symptom Management and Supportive Care
- Psychosocial and Spiritual Care
- Oncologic Emergencies
- Palliative and End-of-Life Care
- Professional Practice and Clinical Performance
Introduction:
This comprehensive assessment is designed to evaluate the advanced clinical
knowledge and decision-making skills required for the Advanced Oncology Certified
Nurse Practitioner (AOCNP) designation. The examination assesses a broad
spectrum of competencies, including the underlying pathophysiology of malignancies,
,complex treatment regimens, and the management of acute and chronic side effects.
Utilizing a combination of foundational multiple-choice questions and complex clinical
scenarios, the test mirrors real-world oncology practice. Emphasis is placed on
evidence-based intervention, critical thinking, and ethical leadership in the care of
diverse patient populations, ensuring that practitioners are prepared to provide high-
quality, comprehensive cancer care from diagnosis through survivorship or end-of-
life.
SECTION ONE: QUESTIONS 1–100
1. A 55-year-old female with Stage III breast cancer is receiving doxorubicin and
cyclophosphamide. She presents with an absolute neutrophil count (ANC) of
450/mm³. Which of the following is the most appropriate next step?
A. Administer the next dose of chemotherapy as scheduled
B. Initiate prophylactic broad-spectrum antibiotics
C. Administer granulocyte colony-stimulating factor (G-CSF)
D. Delay chemotherapy until ANC is > 1,500/mm³
🟢 C. Administer granulocyte colony-stimulating factor (G-CSF)
🔴 RATIONALE: According to NCCN guidelines, patients with an ANC below
,500/mm³ are at high risk for febrile neutropenia; G-CSF is indicated to stimulate bone
marrow production of neutrophils and reduce the duration of severe neutropenia.
2. Which molecular marker is most predictive of response to trastuzumab therapy
in patients with gastric or gastroesophageal junction adenocarcinoma?
A. KRAS mutation
B. HER2/neu overexpression
C. EGFR amplification
D. MSI-H status
🟢 B. HER2/neu overexpression
🔴 RATIONALE: Trastuzumab is a monoclonal antibody that targets the HER2
protein; therefore, overexpression of HER2/neu is the specific requirement for its
efficacy in gastric malignancies.
3. A patient undergoing radiation therapy for head and neck cancer develops
Grade 3 mucositis. What is the priority nursing intervention?
A. Encouraging the use of alcohol-based mouthwashes
B. Assessing nutritional intake and pain management
, C. Prescribing systemic corticosteroids
D. Implementing oral cryotherapy during radiation sessions
🟢 B. Assessing nutritional intake and pain management
🔴 RATIONALE: Grade 3 mucositis significantly impacts the ability to swallow and
maintain hydration; management focuses on adequate analgesia and ensuring the
patient does not become malnourished or dehydrated.
4. Which of the following best describes the mechanism of action of immune
checkpoint inhibitors like pembrolizumab?
A. Direct lysis of tumor cells via oxidative stress
B. Inhibition of the VEGF pathway to prevent angiogenesis
C. Blocking the PD-1/PD-L1 interaction to restore T-cell activity
D. Binding to CD20 on B-cells to initiate apoptosis
🟢 C. Blocking the PD-1/PD-L1 interaction to restore T-cell activity
🔴 RATIONALE: Pembrolizumab prevents the PD-1 receptor on T-cells from binding
to its ligands on tumor cells, effectively "releasing the brakes" on the immune system
to recognize and attack cancer.
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains:
- Scientific Basis for Practice
- Health Promotion, Screening, and Early Detection
- Diagnosis and Staging
- Treatment Modalities (Chemotherapy, Radiation, Surgery, Immunotherapy)
- Symptom Management and Supportive Care
- Psychosocial and Spiritual Care
- Oncologic Emergencies
- Palliative and End-of-Life Care
- Professional Practice and Clinical Performance
Introduction:
This comprehensive assessment is designed to evaluate the advanced clinical
knowledge and decision-making skills required for the Advanced Oncology Certified
Nurse Practitioner (AOCNP) designation. The examination assesses a broad
spectrum of competencies, including the underlying pathophysiology of malignancies,
,complex treatment regimens, and the management of acute and chronic side effects.
Utilizing a combination of foundational multiple-choice questions and complex clinical
scenarios, the test mirrors real-world oncology practice. Emphasis is placed on
evidence-based intervention, critical thinking, and ethical leadership in the care of
diverse patient populations, ensuring that practitioners are prepared to provide high-
quality, comprehensive cancer care from diagnosis through survivorship or end-of-
life.
SECTION ONE: QUESTIONS 1–100
1. A 55-year-old female with Stage III breast cancer is receiving doxorubicin and
cyclophosphamide. She presents with an absolute neutrophil count (ANC) of
450/mm³. Which of the following is the most appropriate next step?
A. Administer the next dose of chemotherapy as scheduled
B. Initiate prophylactic broad-spectrum antibiotics
C. Administer granulocyte colony-stimulating factor (G-CSF)
D. Delay chemotherapy until ANC is > 1,500/mm³
🟢 C. Administer granulocyte colony-stimulating factor (G-CSF)
🔴 RATIONALE: According to NCCN guidelines, patients with an ANC below
,500/mm³ are at high risk for febrile neutropenia; G-CSF is indicated to stimulate bone
marrow production of neutrophils and reduce the duration of severe neutropenia.
2. Which molecular marker is most predictive of response to trastuzumab therapy
in patients with gastric or gastroesophageal junction adenocarcinoma?
A. KRAS mutation
B. HER2/neu overexpression
C. EGFR amplification
D. MSI-H status
🟢 B. HER2/neu overexpression
🔴 RATIONALE: Trastuzumab is a monoclonal antibody that targets the HER2
protein; therefore, overexpression of HER2/neu is the specific requirement for its
efficacy in gastric malignancies.
3. A patient undergoing radiation therapy for head and neck cancer develops
Grade 3 mucositis. What is the priority nursing intervention?
A. Encouraging the use of alcohol-based mouthwashes
B. Assessing nutritional intake and pain management
, C. Prescribing systemic corticosteroids
D. Implementing oral cryotherapy during radiation sessions
🟢 B. Assessing nutritional intake and pain management
🔴 RATIONALE: Grade 3 mucositis significantly impacts the ability to swallow and
maintain hydration; management focuses on adequate analgesia and ensuring the
patient does not become malnourished or dehydrated.
4. Which of the following best describes the mechanism of action of immune
checkpoint inhibitors like pembrolizumab?
A. Direct lysis of tumor cells via oxidative stress
B. Inhibition of the VEGF pathway to prevent angiogenesis
C. Blocking the PD-1/PD-L1 interaction to restore T-cell activity
D. Binding to CD20 on B-cells to initiate apoptosis
🟢 C. Blocking the PD-1/PD-L1 interaction to restore T-cell activity
🔴 RATIONALE: Pembrolizumab prevents the PD-1 receptor on T-cells from binding
to its ligands on tumor cells, effectively "releasing the brakes" on the immune system
to recognize and attack cancer.
